Harborside


CB2 Insights Inc.

CNSX: CBII


Canadian symbol: CBII.CN
US symbol: CBIIF


mrq = Most Recent Quarter
ttm = Trailing Twelve Months
yoy = Year Over Year
lfy = Last Fiscal Year
fye = Fiscal Year Ending
fy = Forward Year
Shares outstanding is taken from the most recently filed quarterly or annual report and Market Cap is calculated using shares outstanding.

Fundamentals are updated every day.
Full screen




Cannabis Market and Business News

Real-time cannabis business news from hundreds of sources. Never miss the news that matters the most.




Company News Date
CBII.CN
CB2 Insights
7 months ago
CBII.CN
CB2 Insights
7 months ago
CBII.CN
CB2 Insights
8 months ago
CBII.CN
CB2 Insights
9 months ago
CBII.CN
CB2 Insights
9 months ago
CBII.CN
CB2 Insights
10 months ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
1 year ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago
CBII.CN
CB2 Insights
2 years ago



Insiders transactions are updated every hour.
Coming Soon

Search SEDAR Filings

Company Name:
Document Type:
Start Date:
End Date:

Press Releases by CB2 Insights Inc.


Skylight Health Reports Q3 Results Achieving Consecutive Quarter and YTD Positive Adjusted EBITDA

Skylight Health Reports Q3 Results Achieving Consecutive Quarter and YTD Positive Adjusted EBITDA

Gross revenues of $3.3 million with a robust gross margin of 71%. Revenue does not include contribution from recently announced acquisitions.Adjusted EBITDA earnings of $331,122, representing its second consecutive quarter of positive Adjusted EBITDA.Year-to-date Adjusted EBITDA profitability of $108,894 compared to an Adjusted EBITDA los... Read More...
CB2 Insights Announces Results of Special Shareholders Meeting and Schedule for Q3 2020 Earnings Call

CB2 Insights Announces Results of Special Shareholders Meeting and Schedule for Q3 2020 Earnings Call

CB2 receives majority shareholder approval for all 3 resolutions proposed.CB2 will release Q3 2020 financial results and MD&A after market close on Monday November 30th, 2020 and subsequently host its earnings call on Tuesday December 1, 2020 at 9 am EDT.CB2 will begin trading under its new name, Skylight Health Group Inc., and new ti... Read More...
CB2 Insights to Acquire Colorado Primary Care Medical Clinic with $2.5 million in Revenue and Positive EBITDA

CB2 Insights to Acquire Colorado Primary Care Medical Clinic with $2.5 million in Revenue and Positive EBITDA

CB2 enters into binding Letter of Intent to acquire APEX Family Medical.APEX generated over CAD 2.5 million in revenues in fiscal 2019 and CAD 0.5 million in net income.Currently services over 5,000 patients in the Greater Denver area, with over 30 years of history.APEX will strengthen CB2’s clinical footprint in Colorado, accelerating th... Read More...
CB2 Insights Announces Upsize to Bought Deal Public Offering to C$5M

CB2 Insights Announces Upsize to Bought Deal Public Offering to C$5M

/NOT FOR DISTRIBUTION TO THE U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, Oct. 29, 2020 - CB2 Insights (CSE:CBII) (OTCQB: CBIIF) ("CB2" or the "Company") is pleased to announce that it has amended the terms of its previously announced offering of Common Shares (as defined below). Under the amended terms of the Offerin... Read More...
CB2 Insights enters Washington with acquisition of Primary Care Medical Clinic with $0.7 million in Revenue and Positive EBITDA

CB2 Insights enters Washington with acquisition of Primary Care Medical Clinic with $0.7 million in Revenue and Positive EBITDA

Washington-based Tacoma medical clinic owned by Dr. Jackson has been providing Primary Care Services to over 10,000 patients in University Place and surrounding regions.In 2019, the clinic generated CAD 0.7 million in revenues and CAD 0.1 million in net income.CB2 Insights will continue to expand services offered by Dr. Jackson including ... Read More...
CB2 Insights announces debt conversion of $3M USD held by Merida Capital and extinguishes all long-term debt liabilities

CB2 Insights announces debt conversion of $3M USD held by Merida Capital and extinguishes all long-term debt liabilities

Merida Capital has agreed to an early conversion of their outstanding debt note of $3M USDMerida will be granted 10,412,250 shares at the calculated 8-day VWAP of $0.38 CADMerida demonstrates its continued support of the Company’s goal of becoming one of the largest multi-disciplinary healthcare operators in the USThe Company further stre... Read More...
CB2 Insights to Present at the Virtual Gravitas Technology and Diversified Investor Day

CB2 Insights to Present at the Virtual Gravitas Technology and Diversified Investor Day

TORONTO, Oct. 13, 2020 -- CB2 Insights (the “Company” or “CB2”) (CSE:CBII OTCQB:CBIIF), one of the largest integrative healthcare systems in the United States, is pleased to announce it will be participating in the Gravitas Technology and Diversified Investor Day taking place Thursday, October 15th, 2020 virtually.CB2’s Chief Executive Of... Read More...
CB2 Insights Announces Acquisition of Texas-based Primary Care Medical & Wellness Clinic with $1.6 million in Revenue and Positive EBITDA

CB2 Insights Announces Acquisition of Texas-based Primary Care Medical & Wellness Clinic with $1.6 million in Revenue and Positive EBITDA

Texas-based Maverick County Medical has been providing Primary Care Services to over 10,300 patients in Eagle Pass and surrounding regions.In 2019, Maverick County Medical generated CAD 1.6 million in revenues and CAD 0.29 million in net income.CB2 Insights will continue to expand services offered by Maverick County Medical including depl... Read More...
CB2 Insights Offers Primary Care Services via Telehealth to Over 100,000 patients across 12 US States

CB2 Insights Offers Primary Care Services via Telehealth to Over 100,000 patients across 12 US States

CB2 Insights, provides healthcare services through brick and mortar clinics and a virtual telemedicine platform to a network of over 100,000 patients across 12 States;The Company recently announced profitability in Q2 2020, free cash flow and an oversubscribed private placement of $CAD 5.13 million;The Company generated $CAD 14 million in... Read More...
CB2 Insights Announces Closing of Upsized and Oversubscribed Private Placement

CB2 Insights Announces Closing of Upsized and Oversubscribed Private Placement

TORONTO, Sept. 25, 2020 -- CB2 Insights Inc. (“CB2” or the “Company”) (CSE: CBII; OTCQB: CBIIF), one of the largest integrative healthcare systems in the United States, is pleased to announce that it has upsized and closed its previously announced non-brokered private placement financing (the "Placement") of units of the Company (the "Uni... Read More...
CB2 Insights Announces $3,000,000 Private Placement Led by Merida Capital

CB2 Insights Announces $3,000,000 Private Placement Led by Merida Capital

TORONTO, Sept. 03, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), one of the largest integrative healthcare systems in the United States, is pleased to announce that it intends to complete a non-brokered private placement of up to 20,000,000 units ("Unit") of the Company at a price of $0.15 per Unit for aggregate ... Read More...
CB2 Insights Announces First EBITDA-Positive Quarter in Company's History

CB2 Insights Announces First EBITDA-Positive Quarter in Company’s History

TORONTO, Aug. 31, 2020 -- CB2 Insights Inc. (“CB2” or the “Company”) (CSE: CBII; OTCQB: CBIIF), one of the largest integrative healthcare systems in the United States, today reported its Q2 2020 consolidated financial results for the period ended June 30, 2020. Additional information concerning the Company, including its unaudited condens... Read More...
CB2 Insights Partners with the Freas Medical Advisors to Expand Healthcare Services in Maryland

CB2 Insights Partners with the Freas Medical Advisors to Expand Healthcare Services in Maryland

Freas Medical Advisors bring over 40 years of healthcare experience in the US through a network of healthcare facilities including pain management and nursing home centersCB2 Insights currently provides medical services to patients in Maryland through virtual telehealth and physical clinics through its Skylight Health Direct Primary Care ... Read More...
CB2 Insights to Host Q2 2020 Earnings Call on September 1st, 2020

CB2 Insights to Host Q2 2020 Earnings Call on September 1st, 2020

TORONTO, Aug. 25, 2020 -- CB2 Insights Inc. (“CB2” or the “Company”) (CSE: CBII; OTCQB: CBIIF), will be hosting its Q2 2020 earnings call on Tuesday, September 1st, 2020 at 9:00 a.m. Eastern Daylight Time (EDT).CB2 will issue a press release and file its interim financial statements and interim Quarterly Management Discussion and Analysis... Read More...
CB2 Insights Adds Insurance Industry Veteran Pam Galassini to its Leadership Team

CB2 Insights Adds Insurance Industry Veteran Pam Galassini to its Leadership Team

Galassini brings more than 20 years of experience in the Insurance and Payor industry as a former Medco Health Solutions, Inc executiveGalassini will help drive growth for CB2 in developing a sales channel with small-to medium-sized businesses (“SMB”) in the United States for Skylight Health Direct Primary Care servicesSMB’s represent nea... Read More...
CB2 Insights Technology Platform Selected by Dharma Pharmaceuticals to Study Real-World Health Outcomes

CB2 Insights Technology Platform Selected by Dharma Pharmaceuticals to Study Real-World Health Outcomes

Dharma will license the Company’s proprietary technology platform “Sail” to use at the point of care within Dharma dispensaries and its network of support centers in Virginia.Sail will be used to monitor, track and generate insights on patient health outcomes on Dharma’s product portfolio.Dharma will use the anonymized data to support pos... Read More...
CB2 Insights Addresses Massive Healthcare Gap in Florida with its Skylight Direct Primary Care Membership

CB2 Insights Addresses Massive Healthcare Gap in Florida with its Skylight Direct Primary Care Membership

TORONTO, July 16, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), announces today, that its Skylight Health Direct Primary Care service will now be available for patients in Florida who have lost healthcare coverage due to job losses during the COVID-19 Pandemic.Skylight Health (“Skylight”) is a Direct Primary Care... Read More...
CB2 Insights Announces Quarterly Revenue of $2.93 million for Q1 2020. EBITDA Nears Breakeven.

CB2 Insights Announces Quarterly Revenue of $2.93 million for Q1 2020. EBITDA Nears Breakeven.

TORONTO, July 14, 2020 -- CB2 Insights Inc. (“CB2” or the “Company”) (CSE: CBII; OTCQB: CBIIF), one of the largest integrative healthcare systems in the United States, today reported its Q1 2020 consolidated financial results for the period ended March 31, 2020. Additional information concerning the Company, including its unaudited conden... Read More...
CB2 Insights Launches Health Pulse – A Monthly Medical Report Studying and Assessing Real-World Health Outcomes

CB2 Insights Launches Health Pulse – A Monthly Medical Report Studying and Assessing Real-World Health Outcomes

TORONTO, July 09, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), has launched the first in a series of monthly medical reports derived from real-world clinical treatments on a variety of healthcare conditions and modalities across the United States, Canada and United Kingdom.The Company currently monitors, assesse... Read More...
CB2 Insights to Host Q1 2020 Earnings Call on July 15, 2020

CB2 Insights to Host Q1 2020 Earnings Call on July 15, 2020

TORONTO, July 08, 2020 -- CB2 Insights Inc. (“CB2” or the “Company”) (CSE: CBII; OTCQB: CBIIF), will be hosting its Q1 2020 earnings call on Wednesday, July 15, 2020 at 9:00 a.m. Eastern Daylight Time (EDT).CB2 will issue a press release and file its interim financial statements and interim Quarterly Management Discussion and Analysis (“M... Read More...
CB2 Insights Announces Q1 Financial Statements to be filed on or before July 14, 2020

CB2 Insights Announces Q1 Financial Statements to be filed on or before July 14, 2020

TORONTO, June 29, 2020 -- CB2 Insights Inc. (“CB2” or the “Company”) (CSE: CBII; OTCQB: CBIIF), announces that it intends to rely on the temporary blanket relief for market participants published on March 23, 2020 (the “Blanket Order”) by the Canadian Securities Administrators (the “CSA”) which provides for a 45-day extension to file its ... Read More...
CB2 Insights Announces Record Annual Revenue of $13.4 million for FY 2019 Sequential Growth of 25%

CB2 Insights Announces Record Annual Revenue of $13.4 million for FY 2019 Sequential Growth of 25%

TORONTO, June 18, 2020 -- CB2 Insights (CSE: CBII; OTCQB: CBIIF) (“CB2” or the “Company”), one of the largest integrative healthcare system in the United States, today reported its audited consolidated financial results for the year ended December 31, 2019. Additional information concerning the Company, including its unaudited condensed c... Read More...
CB2 Insights Announces Amendments to Promissory Note held by Merida Capital Partners

CB2 Insights Announces Amendments to Promissory Note held by Merida Capital Partners

TORONTO, June 18, 2020 -- CB2 Insights (CSE: CBII; OTCQB: CBIIF) (“CB2” or the “Company”), announces that it has amended the terms of its issued and outstanding promissory note held by Merida Capital Partners (“Merida”), which is designed to help the Company achieve its long term growth plans and drive continued profitability.Amendment to... Read More...
CB2 Insights Announces Delay in Filing Annual Financial Statements

CB2 Insights Announces Delay in Filing Annual Financial Statements

TORONTO, June 15, 2020 -- CB2 Insights Inc. (“CB2” or the “Company”) (CSE: CBII; OTCQB: CBIIF) announces that it has been delayed in filing its annual financial statements (the “Annual Financial Statements”) and associated management discussion and analysis (“MD&A”) for the year-ended December 31, 2019, which were required to be filed... Read More...
CB2 Insights Announces Delay in Filing Financials and Year End 2019 Financial Results Conference Call

CB2 Insights Announces Delay in Filing Financials and Year End 2019 Financial Results Conference Call

TORONTO, June 10, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), announces an update further to its news release of April 20, 2020, with respect to: (i) the filing its audited annual financial statements for the year ended December 31, 2019 and the related management discussion and analysis (“MD&A”); and (ii) ... Read More...
CB2 Insights Announces Unaudited Profitability in April and Continued Execution of its Business Plan

CB2 Insights Announces Unaudited Profitability in April and Continued Execution of its Business Plan

TORONTO, May 07, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), has announced that it has achieved its target of reaching profitability. On an unaudited basis, the Company has seen positive EBITDA for April 2020. Amidst the ever-evolving COVID-19 pandemic, the Company continues to work hard to prioritize achieving... Read More...
CB2 Insights Introduces Insurable Medical Services to Patients in the United States with Launch of Skylight Health Group

CB2 Insights Introduces Insurable Medical Services to Patients in the United States with Launch of Skylight Health Group

TORONTO, April 29, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), has announced that it has officially launched its newest division Skylight Health Group (“SHG”) as part of its clinical operations in the United States. SHG will immediately provide a range of integrated health services from primary medical care, to... Read More...
CB2 Insights Completes Purchase of Colorado-based Relaxed Clarity with Surpassed Initial Targets and Provides Additional Corporate Updates

CB2 Insights Completes Purchase of Colorado-based Relaxed Clarity with Surpassed Initial Targets and Provides Additional Corporate Updates

TORONTO, April 20, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), has announced that it has completed the terms of the purchase agreement of Colorado-based Rae of Sunshine Health Services (“ROSH”; “Relaxed Clarity”).  CB2 announced the purchase and took over operations for the multi-location clinic group in April ... Read More...
CB2 Insights Announces Delay in Filing Under CSA Instrument Governing Relief under COVID-19 Duress

CB2 Insights Announces Delay in Filing Under CSA Instrument Governing Relief under COVID-19 Duress

TORONTO, April 15, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), has announced that due to circumstances created by the COVID – 19 pandemic it will not be filing its Financial Statements for the Fiscal Year ended December 31, 2020 by the scheduled due date of April 30, 2020 (as required by section 4.4(b) of Natio... Read More...
CB2 Insights Launches Industry's First Medical Cannabis Insights Dashboard for All Medical Cannabis Stakeholders

CB2 Insights Launches Industry’s First Medical Cannabis Insights Dashboard for All Medical Cannabis Stakeholders

TORONTO, March 30, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, has launched the medical cannabis industry’s first interactive dashboard which gives any industry stakeholders acc... Read More...
CB2 Insights Appoints Healthcare Industry Expert and Former IQVIA Executive Tom Brogan to its Board of Directors

CB2 Insights Appoints Healthcare Industry Expert and Former IQVIA Executive Tom Brogan to its Board of Directors

TORONTO, Jan. 29, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, is pleased to announce the appointment of Tom Brogan, as an independent director to CB2’s Board of Directors. Effec... Read More...
CB2 Insights Announces Completion of Payment of New Jersey Alternative Medicine

CB2 Insights Announces Completion of Payment of New Jersey Alternative Medicine

TORONTO, Jan. 27, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announces it has completed all payment obligations for the June 2019 acquisition of New Jersey Alternative Medicine... Read More...
CB2 Insights 2019 Year In Review – A Message from CEO and Co-Founder Pradyum Sekar

CB2 Insights 2019 Year In Review – A Message from CEO and Co-Founder Pradyum Sekar

TORONTO, Jan. 08, 2020 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, today released its CEO’s 2019 Year In Review.  The letter, which has also been sent to Investors, provides an updat... Read More...
CB2 Insights Announces Industry's First Full-Scale Hemp-based Cannabidiol (CBD) Prospective Trial in Partnership with GL Brands (Formerly Freedom Leaf Inc.)

CB2 Insights Announces Industry’s First Full-Scale Hemp-based Cannabidiol (CBD) Prospective Trial in Partnership with GL Brands (Formerly Freedom Leaf Inc.)

Prospective trial marks first-of-its-kind study on the efficacy and safety of hemp-based CBD treatment focused on patients with anxietyAnnouncement follows the passage of the 2018 US Farm Bill which legalized the mass production of hemp, a form of cannabis with lower THC levels than marijuana, across the United StatesPartnership follows t... Read More...
CB2 Insights Launches Warrant Incentive Program

CB2 Insights Launches Warrant Incentive Program

TORONTO, Dec. 11, 2019 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence-driven from the point-26of-care to the medical cannabis community, announces a warrant exercise incentive program (the “Program”) which has been implemented to encourage the exerci... Read More...
CB2 Insights Announces Collaboration with FCM Global to Support Medical Cannabis R&D in Colombia

CB2 Insights Announces Collaboration with FCM Global to Support Medical Cannabis R&D in Colombia

TORONTO, Dec. 03, 2019 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence-driven from the point-of-care to the medical cannabis community, today announced that it is partnering with Licensed Producer FCM Global (“FCM”), the first Colombian cannabis compa... Read More...
CB2 Insights to Participate at Piper Jaffray’s 31st Annual Healthcare Conference

CB2 Insights to Participate at Piper Jaffray’s 31st Annual Healthcare Conference

TORONTO, Nov. 14, 2019 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence-driven from the point-of-care to the medical cannabis community, today announced Prad Sekar, CEO of CB2 Insights will be participating in a panel discussion and meeting with invest... Read More...
CB2 Insights Announces Record Revenue of $4.2 million for the Third Quarter 2019; Sequential Growth of 29%

CB2 Insights Announces Record Revenue of $4.2 million for the Third Quarter 2019; Sequential Growth of 29%

TORONTO, Nov. 08, 2019 -- CB2 Insights (CSE:CBII; OTCQB: CBIIF) (“CB2” or the “Company”), a leading data-driven company focused on bringing real-world evidence driven from the point-of-care to the medical cannabis community, announced its results for the three and nine months ended September 30, 2019. All figures are reported in Canadian ... Read More...
CB2 Insights Announces Record Preliminary Unaudited Q3 2019 Revenue of $4.2 Million and Details for Earnings Call

CB2 Insights Announces Record Preliminary Unaudited Q3 2019 Revenue of $4.2 Million and Details for Earnings Call

CB2 Insights’ Q3 2019 preliminary unaudited revenue saw a sequential growth of approximately 29% compared to the previous quarterCompany’s Q3 preliminary Adjusted-EBITDA loss was significantly reduced by 64% compared to the previous quarterAfter three acquisitions in the year, CB2 Insights now owns and operates one of the the largest netw... Read More...
CB2 Insights Licenses Electronic Data Capture Software to MyAccess Clinics for Use In the UK

CB2 Insights Licenses Electronic Data Capture Software to MyAccess Clinics for Use In the UK

Company strengthens market presence in United Kingdom with licensing of Electronic Data Capture Technology in partnership with UK-based MyAccess ClinicsMyAccess Clinics to use CB2’s software within multi-clinic operation in the UK for data input and managementSoftware will allow MyAccess Clinics to capture comprehensive data sets related ... Read More...
CB2 Insights Announces Appointment of Medical Director in Colombia and Enters Market with Cannabis Research Focus

CB2 Insights Announces Appointment of Medical Director in Colombia and Enters Market with Cannabis Research Focus

Company recruits prominent Colombian naturopathic and integrative medicine physician Dr. Paola Cubillos, MD, ND to lead medical cannabis research programs to advance emerging marketRapid growth in market presence from Licensed Producers and cannabis-focused product manufacturers create prime conditions to immediately leverage Company’s te... Read More...
CB2 Insights Reports Second Quarter Fiscal 2019 Financial Results, Sees Positive Impact from New Acquisitions

CB2 Insights Reports Second Quarter Fiscal 2019 Financial Results, Sees Positive Impact from New Acquisitions

TORONTO, Aug. 28, 2019 -- CB2 Insights (CSE:CBII; OTCQB:CBIIF) (“CB2” or the “Company”), a leading technology company focused on mainstreaming medical cannabis to the healthcare industry through Real World Evidence (“RWE”), today reported its results for the second quarter of 2019.  Additional information concerning the Company, incl... Read More...
Coming Soon.

Delayed data (1h)


Share this page